Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation (Oncogene, (2020), 39, 9, (1846-1859), 10.1038/s41388-019-1104-z)

Ying Jin; Hua Bao; Xiuning Le; Xiaojun Fan; Ming Tang; Xun Shi; Jun Zhao; Junrong Yan; Yang Xu; Kelly Quek; Yasir Y. Elamin; Jianhua Zhang; P. Andrew Futreal; Ignacio I. Wistuba; John V. Heymach; Guangyuan Lou; Lan Shao; Qiong He; Chen Lin; Xue Wu; Yang W. Shao; Xiaonan Wang; Jiachen He; Yamei Chen; Justin Stebbing; Ming Chen; Jianjun Zhang; Xinmin Yu

doi:10.1038/s41388-019-1143-5

Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation (Oncogene, (2020), 39, 9, (1846-1859), 10.1038/s41388-019-1104-z)

Ying Jin, Hua Bao, Xiuning Le, Xiaojun Fan, Ming Tang, Xun Shi, Jun Zhao, Junrong Yan, Yang Xu, Kelly Quek, Yasir Y. Elamin, Jianhua Zhang, P. Andrew Futreal, Ignacio I. Wistuba, John V. Heymach, Guangyuan Lou, Lan Shao, Qiong He, Chen Lin, Xue WuYang W. Shao, Xiaonan Wang, Jiachen He, Yamei Chen, Justin Stebbing, Ming Chen, Jianjun Zhang, Xinmin Yu

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

The original version of this Article omitted the following from the Acknowledgements: Professor Stebbing sits on SABs for Celltrion, Singapore Biotech, Vor Biopharma, TLC Biopharmaceuticals and Benevolent AI, has consulted with Lansdowne partners, Vitruvian and Social Impact Capital and Chairs the Board of Directors for BB Biotech Healthcare Trust and Xerion Healthcare. This has now been corrected in both the PDF and HTML versions of the Article.

Original language	English (US)
Pages (from-to)	2027
Number of pages	1
Journal	Oncogene
Volume	39
Issue number	9
DOIs	https://doi.org/10.1038/s41388-019-1143-5
State	Published - Feb 27 2020

ASJC Scopus subject areas

Molecular Biology
Genetics
Cancer Research

Access to Document

10.1038/s41388-019-1143-5

Fingerprint

Dive into the research topics of 'Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation (Oncogene, (2020), 39, 9, (1846-1859), 10.1038/s41388-019-1104-z)'. Together they form a unique fingerprint.

Cite this

Jin, Y., Bao, H., Le, X., Fan, X., Tang, M., Shi, X., Zhao, J., Yan, J., Xu, Y., Quek, K., Elamin, Y. Y., Zhang, J., Futreal, P. A., Wistuba, I. I., Heymach, J. V., Lou, G., Shao, L., He, Q., Lin, C., ... Yu, X. (2020). Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation (Oncogene, (2020), 39, 9, (1846-1859), 10.1038/s41388-019-1104-z). Oncogene, 39(9), 2027. https://doi.org/10.1038/s41388-019-1143-5

Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation (Oncogene, (2020), 39, 9, (1846-1859), 10.1038/s41388-019-1104-z). / Jin, Ying; Bao, Hua; Le, Xiuning et al.
In: Oncogene, Vol. 39, No. 9, 27.02.2020, p. 2027.

Research output: Contribution to journal › Comment/debate › peer-review

Jin, Y, Bao, H, Le, X, Fan, X, Tang, M, Shi, X, Zhao, J, Yan, J, Xu, Y, Quek, K, Elamin, YY, Zhang, J, Futreal, PA , Wistuba, II , Heymach, JV, Lou, G, Shao, L, He, Q, Lin, C, Wu, X, Shao, YW, Wang, X, He, J, Chen, Y, Stebbing, J, Chen, M, Zhang, J & Yu, X 2020, 'Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation (Oncogene, (2020), 39, 9, (1846-1859), 10.1038/s41388-019-1104-z)', Oncogene, vol. 39, no. 9, pp. 2027. https://doi.org/10.1038/s41388-019-1143-5

@article{cc65b7789cbb4543afd53cf0a958e488,

title = "Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation (Oncogene, (2020), 39, 9, (1846-1859), 10.1038/s41388-019-1104-z)",

abstract = "The original version of this Article omitted the following from the Acknowledgements: Professor Stebbing sits on SABs for Celltrion, Singapore Biotech, Vor Biopharma, TLC Biopharmaceuticals and Benevolent AI, has consulted with Lansdowne partners, Vitruvian and Social Impact Capital and Chairs the Board of Directors for BB Biotech Healthcare Trust and Xerion Healthcare. This has now been corrected in both the PDF and HTML versions of the Article.",

author = "Ying Jin and Hua Bao and Xiuning Le and Xiaojun Fan and Ming Tang and Xun Shi and Jun Zhao and Junrong Yan and Yang Xu and Kelly Quek and Elamin, {Yasir Y.} and Jianhua Zhang and Futreal, {P. Andrew} and Wistuba, {Ignacio I.} and Heymach, {John V.} and Guangyuan Lou and Lan Shao and Qiong He and Chen Lin and Xue Wu and Shao, {Yang W.} and Xiaonan Wang and Jiachen He and Yamei Chen and Justin Stebbing and Ming Chen and Jianjun Zhang and Xinmin Yu",

note = "Publisher Copyright: {\textcopyright} 2019, The Author(s), under exclusive licence to Springer Nature Limited.",

year = "2020",

month = feb,

day = "27",

doi = "10.1038/s41388-019-1143-5",

language = "English (US)",

volume = "39",

pages = "2027",

journal = "Oncogene",

issn = "0950-9232",

publisher = "Nature Publishing Group",

number = "9",

}

TY - JOUR

T1 - Correction

T2 - Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation (Oncogene, (2020), 39, 9, (1846-1859), 10.1038/s41388-019-1104-z)

AU - Jin, Ying

AU - Bao, Hua

AU - Le, Xiuning

AU - Fan, Xiaojun

AU - Tang, Ming

AU - Shi, Xun

AU - Zhao, Jun

AU - Yan, Junrong

AU - Xu, Yang

AU - Quek, Kelly

AU - Elamin, Yasir Y.

AU - Zhang, Jianhua

AU - Futreal, P. Andrew

AU - Wistuba, Ignacio I.

AU - Heymach, John V.

AU - Lou, Guangyuan

AU - Shao, Lan

AU - He, Qiong

AU - Lin, Chen

AU - Wu, Xue

AU - Shao, Yang W.

AU - Wang, Xiaonan

AU - He, Jiachen

AU - Chen, Yamei

AU - Stebbing, Justin

AU - Chen, Ming

AU - Zhang, Jianjun

AU - Yu, Xinmin

PY - 2020/2/27

Y1 - 2020/2/27

N2 - The original version of this Article omitted the following from the Acknowledgements: Professor Stebbing sits on SABs for Celltrion, Singapore Biotech, Vor Biopharma, TLC Biopharmaceuticals and Benevolent AI, has consulted with Lansdowne partners, Vitruvian and Social Impact Capital and Chairs the Board of Directors for BB Biotech Healthcare Trust and Xerion Healthcare. This has now been corrected in both the PDF and HTML versions of the Article.

AB - The original version of this Article omitted the following from the Acknowledgements: Professor Stebbing sits on SABs for Celltrion, Singapore Biotech, Vor Biopharma, TLC Biopharmaceuticals and Benevolent AI, has consulted with Lansdowne partners, Vitruvian and Social Impact Capital and Chairs the Board of Directors for BB Biotech Healthcare Trust and Xerion Healthcare. This has now been corrected in both the PDF and HTML versions of the Article.

UR - http://www.scopus.com/inward/record.url?scp=85080827245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85080827245&partnerID=8YFLogxK

U2 - 10.1038/s41388-019-1143-5

DO - 10.1038/s41388-019-1143-5

M3 - Comment/debate

C2 - 31831835

AN - SCOPUS:85080827245

SN - 0950-9232

VL - 39

SP - 2027

JO - Oncogene

JF - Oncogene

IS - 9

ER -

Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation (Oncogene, (2020), 39, 9, (1846-1859), 10.1038/s41388-019-1104-z)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this